


Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound represented by Formula (1):

[Formula 1]




— , —
is each independently a single bond or a double bond; R¹ and R² may be bonded to each other to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; and R² may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted,


or a salt thereof,

wherein the compound does not include formulae represented by Formula (2) and Formula (3) below:

[Formula 2]



[Formula 3]



2. (Original) A prodrug of the compound according to claim 1.
3. (Original) The compound according to claim 1, wherein Cy is phenyl which may be substituted, or a 5- to 6-membered aromatic monocyclic heterocyclic group which may be substituted.
4. (Original) The compound according to claim 1, wherein Cy is phenyl which may be substituted with a halogen atom.
5. (Original) The compound according to claim 1, wherein R¹ is a hydrogen atom.
6. (Original) The compound according to claim 1, wherein V is -C(O)-.
7. (Original) The compound according to claim 1, wherein W is -N(R²)-.
8. (Original) The compound according to claim 1, wherein X is C₁₋₄ alkylene which may be substituted with a hydrocarbon group which may be substituted, an aromatic heterocyclic group

which may be substituted, a hydroxyl group which may be substituted, amino which may be substituted, carbamoyl which may be substituted or carboxyl which may be esterified.

9. (Original) The compound according to claim 1, wherein X is methylene which may be substituted with a hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted.

10. (Original) The compound according to claim 1, wherein Y is $-\text{C}(\text{O})-$.

11. (Original) The compound according to claim 1, wherein $-\text{W}-\text{X}-\text{Y}-$ is an amino acid residue.

12. (Original) The compound according to claim 1, wherein ring A is a piperidine ring which may be substituted, or a piperazine ring which may be substituted.

13. (Original) The compound according to claim 1, wherein ring B is a monocyclic nitrogen-containing heterocyclic ring which may be substituted.

14. (Original) The compound according to claim 13, wherein the monocyclic nitrogen-containing heterocyclic ring is a piperidine ring, a piperazine ring, a morpholine ring, an imidazoline ring, a pyrrolidine ring, a pyridine ring, an imidazole ring, or a thiazoline ring.

15. (Original) The compound according to claim 1, wherein ring B is a fused nitrogen-containing heterocyclic ring which may be substituted.

16. (Original) The compound according to claim 15, wherein the fused nitrogen-containing heterocyclic ring is a fused pyridine ring, a fused imidazole ring, a fused pyrazole ring, or a fused thiazoline ring.

17. (Original) The compound according to claim 1, wherein Z is a bond or C_{1-6} alkylene.

18. (Original) A compound selected from the group consisting of N-(4-chlorophenyl)-N'-(^(1R)-2,2-dimethyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, N-(4-chlorophenyl)-N'-(2-ethyl-2-hydroxy-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)butyl)urea, N-(4-chlorophenyl)-N'-(^(1S)-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)-2-(methylthio)propyl)urea, and N-(4-chlorophenyl)-N'-(2-methoxy-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, or a salt thereof.

19. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1.

20-23. (Canceled)

24. (Original) A method of inhibiting blood coagulation in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

25. (Original) A method of inhibiting activated blood coagulation factor X in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

26. (Original) A method of preventing and/or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or arteriosclerosis obliterans in mammal which comprises administering an effective amount of the compound according to claim 1 or a prodrug thereof to the mammal.

27-29. (Canceled)

30. (Previously presented) A pharmaceutical composition comprising the compound according to claim 2.